Evidence map›Paper›PMID 34746013›Full record

ArticleFrontiers in oncology2021

Biological Predictors of

Michela Cangemi, Stefania Zanussi, Enrica Rampazzo, Ettore Bidoli, Silvia Giunco, Rosamaria Tedeschi, Chiara Pratesi, Debora Martorelli, Mariateresa Casarotto, Ferdinando Martellotta and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 2 countries.

Michela CangemiDepartment of Biomedical Sciences, University of Sassari, Sassari, Italy.
Stefania ZanussiImmunopathology and Cancer Biomarkers, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy.
Enrica RampazzoDepartment of Surgery, Oncology and Gastroenterology, Section of Oncology and Immunology, University of Padova, Padova, Italy.
Ettore BidoliCancer Epidemiology Unit, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy.
Silvia GiuncoDepartment of Surgery, Oncology and Gastroenterology, Section of Oncology and Immunology, University of Padova, Padova, Italy.
Rosamaria TedeschiMicrobiology and Virology Unit, "S. Maria degli Angeli" Hospital, Pordenone, Italy.
Chiara PratesiClinical Pathology, "S. Maria degli Angeli" Hospital, Pordenone, Italy.
Debora MartorelliImmunopathology and Cancer Biomarkers, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy.
Mariateresa CasarottoImmunopathology and Cancer Biomarkers, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy.
Ferdinando MartellottaDivision of Medical Oncology A, Centro di Riferimento Oncologico (CRO) Aviano, National Cancer Institute, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy.
Ornella SchioppaDivision of Medical Oncology A, Centro di Riferimento Oncologico (CRO) Aviano, National Cancer Institute, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy.
Diego SerrainoCancer Epidemiology Unit, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy.
Agostino SteffanImmunopathology and Cancer Biomarkers, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy.
Anita De RossiDepartment of Surgery, Oncology and Gastroenterology, Section of Oncology and Immunology, University of Padova, Padova, Italy.
Riccardo DolcettiCentre for Cancer Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Emanuela VaccherDivision of Medical Oncology A, Centro di Riferimento Oncologico (CRO) Aviano, National Cancer Institute, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy.
Centro di Riferimento Oncologico · ITAzienda Ospedaliera Santa Maria Degli Angeli · ITUniversity of Padua · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Oncologico Veneto · ITUniversity of Queensland · AUUniversity of Sassari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsAn exploratory longitudinal study was designed based on two serial peripheral blood samples collected at least three months apart. Forty nine SOT patients were selected and stratified by tumor onset during follow-up. Spontaneous T-cell responses to EBV, CMV and tumor associated antigens, EBV-DNA and CMV-DNA loads, and circulating

resultsSignificantly higher levels of circulating

conclusionsAlthough obtained in an exploratory study, our data support the importance of identifying early biomarkers of tumor onset in SOT patients useful to modulate the pace of surveillance visits.

Indexed as

cancercirculating TERT mRNAimmunosuppressiononcological surveillanceT cellstransplant

Identifiers

PMID34746013
PMCPMC8567137
OpenAlexW3209500940

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.